WaveMan
WaveMan · Company
NATR · Natures Sunshine Products Inc
> Search tickers & screens ⌘K
LIVE
← All companies

NATR Natures Sunshine Products (NATR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000275053
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
69
13F, latest reported quarter
Conversions, 180 days
18
Codes C/M, not in net · $0 priced

What the filings say about NATR

Insiders, 180 days
+$1.9M net bought
1 buyer · 4 sellers · 0% of sales under a 10b5-1 plan

Natures Sunshine Products insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, NATURES SUNSHINE PRODUCTS INC insiders bought a net $1.9M of stock across 81 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
BUY
2026-08-19 SECtraded 2026-08-17
20,000
$293.8K
-14.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Aug 10, 2026.
  • The trade is 1.0% of the 1,944,486 shares held after it.
  • No other insider bought within 30 days.
  • 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought about $293.8K of NATR on Aug 17, 2026; 69 funds added in the latest 13F quarter.
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
BUY
2026-08-10 SEC
876
$13.7K
-23.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Aug 7, 2026.
  • The trade is 0.0% of the 1,884,486 shares held after it.
  • No other insider bought within 30 days.
  • 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought about $13.7K of NATR on Aug 10, 2026; 69 funds added in the latest 13F quarter.
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
BUY
2026-08-10 SEC
16,928
$267.5K
-23.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Aug 7, 2026.
  • The trade is 0.9% of the 1,901,414 shares held after it.
  • No other insider bought within 30 days.
  • 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought about $267.5K of NATR on Aug 10, 2026; 69 funds added in the latest 13F quarter.
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
BUY
2026-08-10 SEC
13,072
$206.3K
-23.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Aug 7, 2026.
  • The trade is 0.7% of the 1,914,486 shares held after it.
  • No other insider bought within 30 days.
  • 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought about $206.3K of NATR on Aug 10, 2026; 69 funds added in the latest 13F quarter.
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
BUY
2026-08-10 SEC
10,000
$160.1K
-23.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Aug 7, 2026.
  • The trade is 0.5% of the 1,924,486 shares held after it.
  • No other insider bought within 30 days.
  • 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought about $160.1K of NATR on Aug 10, 2026; 69 funds added in the latest 13F quarter.
81 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 76 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.9M over 180 days
+$2.6M over 90 days · +$2.6M of it by a 10%+ holder
more than 92% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
69 funds bought in last quarter
more than 56% of Pharma & Biotech
Revenue
+5.7% year over year
more than 54% of Pharma & Biotech
Margin
4.1% net margin
more than 76% of Pharma & Biotech
Buybacks
$2.6M repurchased, FY to 2026-06-30
below 83% of Pharma & Biotech
Short interest
6.8% of the float short (float per yahoo 2026-10-26) · 7.5 days to cover · settled 2026-09-30
more than 50% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch NATR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.3%12M
-14%+23%+60%+96%2025-102025-122026-022026-042026-062026-082026-10 2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $500.4K2026-03-13 · Yates Bryant J sold $475.2K2026-03-13 · Norman Daniel C sold $377.2K2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $333.8K2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $331.0K2026-08-17 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $293.8K2026-08-10 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $267.5K2026-05-21 · Brower Nathan G sold $262.4K2026-06-05 · Yates Bryant J sold $238.2K2026-08-10 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $206.3K2026-06-01 · Norman Daniel C sold $200.5K2025-11-12 · Norman Daniel C sold $181.8K2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $167.2K2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $164.6K2026-08-10 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $160.1K2025-11-18 · Lanoy Jonathan David sold $102.2K2026-03-13 · Lanoy Jonathan David sold $98.8K2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $83.1K2025-11-14 · Brower Nathan G sold $79.1K2026-08-06 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $42.1K2025-12-12 · Yates Bryant J sold $37.9K2026-08-06 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $32.7K2026-06-12 · Herbert Kevin R. sold $23.4K2026-06-12 · Herbert Kevin R. sold $18.0K2026-08-07 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $16.5K2026-08-10 · PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. bought $13.7K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NATR: institutional holders (13F)

13F holdings, latest reported quarter
WYNNEFIELD CAPITAL INC
2,473,686 sh
$53.9M
Prescott Group Capital Management, L.L.C.
1,783,097 sh
$38.9M
BlackRock, Inc.
989,020 sh
$21.6M
DIMENSIONAL FUND ADVISORS LP
923,626 sh
$20.1M
AMERICAN CENTURY COMPANIES INC
714,829 sh
$15.6M

Congress trades in NATR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NATR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NATR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
NORTH SQUARE KENNEDY MICROCAP FUND
$417.6K position · as of 2026-05-31
1.3%
North Star Micro Cap Fund
$2.1M position · as of 2026-05-31
1.1%
Boston Partners Small Cap Value Fund II
$3.3M position · as of 2026-05-31
0.4%
First Trust Dow Jones Select MicroCap Index Fund
$1.0M position · as of 2026-06-30
0.4%
Ultra-Small Company Fund
$348.8K position · as of 2026-06-30
0.4%
Franklin Small Cap Enhanced ETF
$405.2K position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Terrence Moorehead
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$2.8M
$94.4K
$1.1M
-2%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.9M bought by insiders over 180 days, 69 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NATR financials

Revenue growth
+5.7%
XBRL, annual
Net margin
4.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$492.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+3.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$18.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.01x
LongTermDebt as filed 2024-03-31 (27 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
12.99x
TTM operating cash flow over LongTermDebt as filed 2024-03-31 (27 months older than the period end) (includes the current portion)
Return on equity
+10.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+7.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+22.1%
operating income after a 34.8% effective tax rate, over LongTermDebt as filed 2024-03-31 (27 months older than the period end) (includes the current portion) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+15.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
12.15x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$135.5M
market value at close 2026-10-26 on 2026-07-24 shares, plus LongTermDebt as filed 2024-03-31 (27 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
+8.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.33x
P/E over trailing EPS growth of 36%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$480.1M$454.4M$445.3M$421.9M
Gross profit$347.7M$324.7M$321.1M$299.8M
Operating income$24.7M$20.1M$18.7M$16.3M
Net income$19.5M$7.7M$15.1M-$390.0K
EPS (diluted)1.060.400.77-0.02
Operating cash flow$35.3M$25.3M$41.2M$710.0K
Cash$93.9M$84.7M$82.4M$60.0M
Long-term debtn/an/a$0$0
Buybacks$16.3M$8.9M$6.4M$13.6M
Dividends paidn/an/an/a$0
SEC XBRL, fiscal years, as known on 2026-10-28

NATR Stock Sonar score 6/7 axes

Find similar shapesCompare

NATR ranks highest on financial health (86th percentile) and profitability (82nd), and lowest on risk and compliance (54th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
82
Inputs
  • Return on equity+10.9% · 85 pct, sector of 545
  • Return on assets+7.0% · 87 pct, sector of 691
  • Return on invested capital+22.1% · 64 pct, sector of 45
  • Return on capital employed+15.8% · 93 pct, sector of 576
Financial health
86
Inputs
  • Debt to equity0.01x · 75 pct, sector of 352
  • Cash flow to debt12.99x · 97 pct, sector of 371
Growth
54
Inputs
  • Revenue growth, YoY+5.7% · 54 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
74
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.9M · 92 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
56
Inputs
  • Funds adding, latest quarter69 · 56 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+6.8% · 50 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.1% · 58 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NATR filings, in plain words

Are Natures Sunshine Products insiders buying or selling NATR?

In the 180 days to 2026-10-28, Natures Sunshine Products insiders were net buyers, a net $1.9M: $2.6M of purchases and $742.4K of sales reported on Form 4, by 1 buyer and 4 sellers.

Read the full summary

In the 180 days to 2026-10-28, Natures Sunshine Products insiders were net buyers of NATR, a net $1.9M across purchases and sales reported on Form 4 by 1 buyer and 4 sellers. Most of that figure, $2.6M, came from a holder of 10% or more rather than an officer or director. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies